stockportfolio.pro
Penumbra, Inc. (PEN)
Healthcare · Medical Devices · NYSE
Penumbra, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.32M | $333.76M | $444.94M | $547.40M | $560.41M | $747.59M | $847.13M | $1.06B | $1.19B | $1.40B |
| Gross profit | $170.83M | $217.14M | $292.53M | $371.96M | $338.18M | $475.38M | $535.21M | $682.64M | $755.00M | $942.44M |
| Net income | $14.81M | $4.66M | $6.60M | $48.46M | $-15.70M | $5.28M | $-2.00M | $90.95M | $14.01M | $177.69M |
| Net margin | 5.6% | 1.4% | 1.5% | 8.9% | -2.8% | 0.7% | -0.2% | 8.6% | 1.2% | 12.7% |
Source: Penumbra, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Penumbra, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PEN in your portfolio →
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Penumbra, Inc. — frequently asked questions
What is Penumbra, Inc.'s revenue?
Penumbra, Inc. (PEN) reported revenue of $1.40B for fiscal year 2025, up 17.5% from the prior year, according to its SEC filings.
Is Penumbra, Inc. profitable?
Yes. PEN earned net income of $177.69M in fiscal 2025, a net margin of 12.7%.
What is PEN's P/E ratio?
Penumbra, Inc. trades at a price-to-earnings ratio of about 73.8 based on the latest data in our nightly-refreshed cache.
How fast is Penumbra, Inc. growing?
PEN's revenue grew at roughly 20.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Penumbra, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.